Correction: Vidal et al. From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment. Int. J. Mol. Sci. 2021, 22, 6740

Vidal, Silvia; Puig, Lluís; Carrascosa-Carrillo, José-Manuel; González-Cantero, Álvaro; Ruiz-Carrascosa, José-Carlos; Velasco-Pastor, Antonio-Manuel

doi:10.3390/ijms23052649

Open AccessCorrection

Correction: Vidal et al. From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment. Int. J. Mol. Sci. 2021, 22, 6740

¹

Institute of Research, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain

²

Hospital Germans Trias i Pujol, 08916 Badalona, Spain

³

Department of Dermatology, Hospital Universitario Ramón y Cajal, M-607, km. 9, 100, 28034 Madrid, Spain

⁴

Facultad de Medicina, Universidad Francisco de Vitoria, Ctra. Pozuelo-Majadahonda KM 1.800, 28223 Pozuelo de Alarcón, Spain

⁵

Hospital Clínico Universitario San Cecilio, 18016 Granada, Spain

⁶

Hospital Arnau de Vilanova, 46015 Valencia, Spain

^*

Author to whom correspondence should be addressed.

Int. J. Mol. Sci. 2022, 23(5), 2649; https://doi.org/10.3390/ijms23052649

Submission received: 13 December 2021 / Accepted: 16 December 2021 / Published: 28 February 2022

(This article belongs to the Special Issue Lymphocyte Signalling and Function in Systemic Autoimmune Diseases)

Download Versions Notes

In the original publication [1], there was a mistake in Figure 1 as published. A new yellow circle has been added to clarify the action of brodalumab on IL-17A, A/F, and F. The three items named TRAF6 (colored in light green) have been substituted for the correct name: TRAF2/5. The corrected Figure 1 appears below. The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. The original publication has also been updated.

Reference

Vidal, S.; Puig, L.; Carrascosa-Carrillo, J.-M.; González-Cantero, Á.; Ruiz-Carrascosa, J.-C.; Velasco-Pastor, A.-M. From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment. Int. J. Mol. Sci. 2021, 22, 6740. [Google Scholar] [CrossRef] [PubMed]

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Share and Cite

MDPI and ACS Style

Vidal, S.; Puig, L.; Carrascosa-Carrillo, J.-M.; González-Cantero, Á.; Ruiz-Carrascosa, J.-C.; Velasco-Pastor, A.-M. Correction: Vidal et al. From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment. Int. J. Mol. Sci. 2021, 22, 6740. Int. J. Mol. Sci. 2022, 23, 2649. https://doi.org/10.3390/ijms23052649

AMA Style

Vidal S, Puig L, Carrascosa-Carrillo J-M, González-Cantero Á, Ruiz-Carrascosa J-C, Velasco-Pastor A-M. Correction: Vidal et al. From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment. Int. J. Mol. Sci. 2021, 22, 6740. International Journal of Molecular Sciences. 2022; 23(5):2649. https://doi.org/10.3390/ijms23052649

Chicago/Turabian Style

Vidal, Silvia, Lluís Puig, José-Manuel Carrascosa-Carrillo, Álvaro González-Cantero, José-Carlos Ruiz-Carrascosa, and Antonio-Manuel Velasco-Pastor. 2022. "Correction: Vidal et al. From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment. Int. J. Mol. Sci. 2021, 22, 6740" International Journal of Molecular Sciences 23, no. 5: 2649. https://doi.org/10.3390/ijms23052649

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Correction: Vidal et al. From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment. Int. J. Mol. Sci. 2021, 22, 6740

Reference

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI